Novo Nordisk plans to test cholesterol-lowering oral solution in phase II trial
In a new phase II trial, Novo Nordisk plans to test the company's cholesterol-lowering PCSK9i inhibitor. As a different feature from the phase I trial, the drug will be tested as an oral treatment.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
This month, Novo Nordisk has initiated a phase II trial with the firm's cholesterol-lowering PCSK9i inhibitor, according to the Danish pharmaceutical firm's Q2 report, published on Wednesday afternoon.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Novo Nordisk upgrades guidance for the rest of the year
For subscribers
